Post on 26-Aug-2018
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 1 -
OKT 3 immunoprophylaxis in human liver transplantation
Muehlbacher F, Steininger R, Laengle F, Sautner T, Gnant M, Goetzinger P, Piza F, Popow T
Transplant P 1989; 21: 2253-4
1
1,096IF:
Adjuvante Therapie einer Pseudomonaspneumonie und -sepsis bei einer immunsupprimiertenPatientin nach orthotoper Lebertransplantation mit einer IgM-angereicherten Immunglobulinloesungund Fibronectin-angereichertem Serum
Sautner T, Graninger G, Gnant M, Jantsch H
Acta Chir Austriaca 1989; 6: 304-5
2
0,000IF:
Prophylaxis with OKT 3 for liver transplantation
Muehlbacher F, Steininger R, Laengle F, Hamilton G, Sautner T, Gnant M, Goetzinger P, Piza F, Popow T
Transplant P 1989; 21 Suppl 2: 25-30
3
1,096IF:
Professionelle Organgewinnung als Vorraussetzung zum Erreichen der notwendigenTransplantationsfrequenz: Erfahrungen mit der Organspende am Transplantationszentrum Wien
Gnant M, Sautner T, Muehlbacher F, Steininger R, Laengle F, Piza F
Wiener Klin Wochenschr 1989; 23: 824-8
4
0,245IF:
Erfahrungen und klinische Ergebnisse nach 99 Verwandtennierentransplantationen
Laengle F, Gnant M, Sautner T, Muehlbacher F, Kretschmer G, Traindl O, Kovarik J, Derfler K, Balcke B, Steger H, HajekA, Piza F
Wiener Klin Wochenschr 1989; 5: 148-51
5
0,216IF:
Pancreatic venous drainage to the portal vein: A new method in human pancreatic transplantation
Muehlbacher F, Gnant M, Auinger M, Steininger R, Klauser R, Prager R, Karnel F
Transplant P 1990; 22: 636-7
6
0,987IF:
Immediate graft function after OLT clears endotoxins
Steininger R, Fuegger R, Hackl W, Hamilton G, Herbst F, Laengle F, Gnant M, Rogy M, Sautner T, Schulz F, MuehlbacherF
Transplant P 1990; 22: 1544-6
7
0,987IF:
Zur Neubewertung der Indikation zur Lebertransplantation
Funovics J, Gnant M, Piza F
Leber-Magen-Darm 1990; 1: 7-11
8
0,227IF:
Homologe Saphenavenen als AV-Shunt zur Hämodialyse: Ein Vergleich zu konventionellenMethoden
Laengle F, Gnant M, Sautner T, Muehlbacher F, Watzinger U, Derfler K, Manker M, Piza F
Angio Arch 1990; 19: 171-3
9
0,000IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 2 -
Aspects and prospects of organ procurement: The Vienna experience
Gnant M
ETCO Newsl 1990; 1: 7-10
10
0,000IF:
The impact of serum lipid parameters on the diagnosis of acute and chronic rejection after orthotopicliver transplantation
Gnant M, Schoental E, Banhegyi C, Steininger R, Sautner T, Goetzinger P, Wamser P, Zekert F, Muehlbacher F
Transplant Proc 1991; 23: 1434-5
11
1,064IF:
Is orthotopic liver transplantation a feasable treatment for secondary cancer of the liver?
Muehlbacher F, Huk I, Steininger R, Gnant M, Goetzinger P, Wamser P, Banhegyi C, Piza F
Transplant P 1991; 23: 1567-8
12
1,064IF:
Soluble interleukin-2 receptor in liver transplant recipients
Stockenhuber F, Gnant M, Apperl A, Steininger R, Sautner T, Balcke P, Muehlbacher F
Transplant P 1991; 23:1417-8
13
1,064IF:
Derzeitiger Therapieplan beim differenzierten Schilddrüsenkarzinom
Roka R, Niederle B, Gnant M, Laengle F, Hausmaninger C, Neuhold N
Chirurg 1991; 62: 518-23
14
0,392IF:
Impact of donor age on graft function in 1180 consecutive kidney recipients
Sautner T, Goetzinger P, Wamser P, Gnant M, Steininger R, Muehlbacher F
Transplant P 1991; 23: 2598-601
15
1,064IF:
The impact of presumed consent law and decentralized organ procurement system on organdonation: quadruplication of number of organ donors
Gnant M, Wamser P, Goetzinger P, Sautner T, Steininger R, Muehlbacher F
Transplant P 1991; 23: 2685-6
16
1,064IF:
Prenephrectomy tissue typing using donor lymph node cells: A reliable and safe way of shorteningcadaver kidney ischemia time
Gnant M, Rosenmayr A, Wamser P, Goetzinger P, Sautner T, Steininger R, Banhegyi C, Muehlbacher F
Transplant P 1991; 23: 2683-4
17
1,064IF:
Der prognostische Stellenwert der Flowzytometrie beim Mammakarzinom: 10-Jahres-Ergebnisseeiner randomisierten Studie
Gnant M, Blijham G, Schemper M, Reiner A, Reiner G, Spona J, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R
Acta chir Austriaca 1991; 2: 43-8
18
0,000IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 3 -
Erfahrungen mit der Lebertransplantation beim Hepatitis-B-Antigen positiver Leberzirrhose
Steininger R, Muehlbacher F, Längle F, Gnant M, Sautner T, Goetzinger P, Walgram M, Penner E, Radaszkiewicz T
Wien Klin Wochschr 1991; 19: 573-6
19
0,243IF:
Transplantation of shipped full-house kidneys versus local poorly matched grafts - does a shortercold ischemic time outweigh a worse match?
Banhegyi C, Sautner T, Gnant M, Goetzinger P, Wamser P, Muehlbacher F
Transplant P 1991; 23: 2610-1
20
1,064IF:
Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation
Steininger R, Muehlbacher F, Hamilton G, Laengle F, Gnant M, Popow T, Sautner T, Goetzinger P, Wamser P,Stockenhuber F, Mirza D, Piza F
Transplant P 1991; 23: 2269-71
21
1,064IF:
Abgeschlossene und derzeit laufende adjuvante Therapieprotokolle bei Patienten mit operablemMammakarzinom
Jakesz R, Hausmaninger H, Depisch D, Kubista E, Samonigg H, Steindorfer P, Schemper M, Gnant M, Kolb R, Krauß K,Manfreda D, Stierer M, Michlmayr G, Fridrik M, Dadak C, Hofbauer F, Horvath W, Zielinski C, Wette V, Oppitz P, DuenserM, Lenzhofer R, Mueller L, Ludwig H; Adler A, Aiginger P, Bauer D, Bauerndorfer T, Beinhauer A, Boeckl O, Brunhofer A,
Acta chir Austriaca 1991; 2: 63-9
22
0,000IF:
Intraoperative course and prognostic significance of Endotoxin, Tumor necrosis factor-alpha andInterleukin-6 in liver transplant recipients
Hamilton G, Prettenhofer M, Zommer A, Hofbauer S, Goetzinger P, Gnant M, Függer R
Immunobiology 1991; 182: 425-39
23
1,576IF:
Cadaveric kidney donation beyond the age of 60 - a comparative analysis of 1180 grafts fromdifferent donor age groups
Sautner T, Gnant M, Goetzinger P, Wamser P, Steininger R, Muehlbacher F
Tranplant Int 1992; 5 Suppl 1: S47-S50
24
0,907IF:
Risk factors for development of panel reactive antibodies and their impact on transplantation outcomein 909 kidney grafts
Sautner T, Gnant M, Banhegyi C, Wamser P, Goetzinger P, Steininger R, Muehlbacher F
Transplant Int 1992; 5 Suppl 1; S116-S120
25
0,907IF:
DNA ploidy and other results of DNA Flow cytometry as prognostic factors in operable breast cancer:10 year results of a randomized study
Gnant M, Blijham G, Reiner A, Reiner G, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R
Eur J Cancer 1992; 28: 711-6
26
2,191IF:
A reliable way of shortening cadaver kidney ischemia time: Prenephrectomy tissue typing usingdonor lymph node cells
Gnant M, Sautner T, Wamser P, Goetzinger P, Rosenmayr A, Muehlbacher F
Tranplant Int 1992; 5 Suppl 1: S722-S724
27
0,907IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 4 -
Repeated HLA mis-match in multiple kidney transplantation - Preliminary results of 146retransplantations in the cyclosporine era
Gnant M, Sautner T, Rosenmayr A, Muehlbacher F
Transplant P 1992; 24: 2466-2468
28
1,125IF:
Breast cancer and timing of surgery during menstrual cycle: A 5-year analysis of 385 premenopausalwomen
Gnant M, Seifert M, Jakesz R, Adler A, Mittlboeck M, Sevelda P
Int J Cancer 1992; 52: 707-712
29
2,917IF:
Laparoskopische Cholecystektomie - Auswertung einer prospektiven Beobachtungsstudie
Fuegger R, Klimann S, Gnant M, Herbst F, Schulz F, Fritsch A
Wien Klin Wochenschr 1992; 104/20: 640-3
30
0,196IF:
Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma
Neuhold N, Laengle F, Gnant M, Hollenstein U, Niederle B
J Cancer Res Clin 1992; 118: 629-634
31
1,820IF:
Gallengangsverletzungen bei laparoskopischer Cholecystektomie
Fuegger R, Klimann S, Gnant M, Schulz F, Fritsch A
Helv Chir Acta 1992; 59: 571-571
32
0,046IF:
Risikofaktoren für die Entstehung lymphozytotoxischer Antikörper und deren Einfluß auf dieOrganfunktion nach Nierentransplantation
Sautner T, Gnant M, Banhegyi C, Wamser P, Goetzinger P, Steininger R, Hajek-Rosenmayr A, Muehlbacher F
Acta chir Austriaca 1992; 24: 354-8
33
0,000IF:
Die experimentelle laparoskopische Sigmaresektion
Fuegger R, Herbst F, Gnant M, Goetzinger P, Sautner T, Windberger U, Siegl H, Losert U, Fritsch A
Min Inv Chir 1992; 1: 167-8
34
0,576IF:
Tolerance induction in human kidney retransplantation: Impact of repeated HLA mismatches in 156second renal grafts
Gnant M, Sautner T, Rosenmayr A, Muehlbacher F
Transplant P 1993; 25: 319-321
35
1,125IF:
Circulating ICAM-1: Novel parameter of renal graft rejection
Stockenhuber F, Kramer G, Pec M, Scentkiraly A, Gnant M, Steininger R, Balcke P, Muehlbacher F
Transplant P 1993; 25: 919-920
36
1,125IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 5 -
Impact of vesicoureteral reflux on graft survival in renal transplantation
Gruenberger T, Gnant M, Sautner T, Hoebarth K, Steininger R, Hofbauer J, Muehlbacher F
Transplant P 1993; 25: 1058-1059
37
1,125IF:
GM-CSF in the treatment of a patient with severe methotrexate intoxication
Steger G, Mader R, Gnant M, Marosi C, Lenz K, Jakesz R
J Intern Med 1993; 233: 499-502
38
1,453IF:
Aneuploidy Fraction but not DNA Index is important for the prognosis of patients with stage I and IIbreast cancer - 10 year results
Gnant M, Blijham G, Schemper M, Reiner A, Reiner G, Spona J, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R
Ann Oncol 1993; 4: 643-650
39
2,064IF:
Mechanisms of tumor necrosis factor-a and interleukin-6 induction during human liver transplantation
Hamilton G, Vogel S, Fuegger R, Gnant M
Mediat Inflamm 1993; 2: 303-307
40
0,870IF:
What do intensive care unit personell think about organ donation? Opinion poll amongst transplantcenters
Wamser P, Goetzinger P, Gnant M, Sautner T, Steininger R, Muehlbacher F
Transplant P 1993; 25:3122-3
41
1,125IF:
Laparoskopische Kolonchirurgie - vom Experiment zu ersten klinischen Erfahrungen
Fuegger R, Herbst F, Gnant M, Sautner T, Goetzinger P, Windberger U, Siegl H, Losert U, Fritsch A
Wien Klin Wochenschr 1993; 105: 544-548
42
0,268IF:
Discontinuing of a permanent information and education program among donors ICUs leads to a 50%decrease of organ donor rates
Wamser P, Goetzinger P, Steininger R, Gnant M, Sautner T, Muehlbacher F
Transplant P 1993; 25: 2988-9
43
1,125IF:
Impact of donor cause of death on renal graft function - a multivariate analysis of 1545 kidneytransplants
Gnant M, Wamser P, Barlan M, Muehlbacher F
Transplant P 1993; 25: 3102-3
44
1,125IF:
The potential impact of Tamoxifen in Breast Cancer Prevention
Goetzinger P, Gnant M, Hochstoeger E, Jakesz R
Onkologie 1993; 16: 297-303
45
0,545IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 6 -
Double modulation of 5-flourouracil by high-dose leucovorin and interferon a2b in advancedcolorectal cancer: A phase I and a phase II study of weekly administration
Steger GG, Mader RM, Djavanmard MP, Gnant M, Locker G, Marosi C, Rainer H, Jakesz R
J Cancer Res Clin Oncol 1994; 120: 314-318
46
1,820IF:
Pharmacokinetics of rac-leucovorin versus [S]-leucovorin in patients with advanced gastrointestinalcancer
Mader RM, Steger GG, Rizovski B, Sieder AE, Locker G, Gnant M, Jakesz R, Rainer H
Brit J Clin Pharmac 1994; 37: 243-248
47
1,922IF:
Reasons for 50% reduction in the number of organ donors within 2 years - opinion poll amongst allICUs of a tranplant centre
Wamser P, Goetzinger P, Barlan M, Gnant M, Hoelzenbein T, Watschinger B, Muehlbacher F
Transplant Int 1994; 7 [Suppl 1]: S668-671
48
0,907IF:
Reasons for 50% reduction in the number of organ donors within 2 years - opinion poll amongst allICUs of a tranplant centre
Wamser P, Goetzinger P, Barlan M, Gnant M, Hoelzenbein T, Watschinger B, Muehlbacher F
Eurotransplant Newsletter 1994; 116: 6-9
48A
0,000IF:
Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation withprognosis
Rudas M, Gnant M, Mittlboeck M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A
Breast Cancer Res Tr 1994; 32: 165-175
49
2,479IF:
Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity inbreast cancer
Fiegl M, Tueni C, Schenk T, Jakesz R, Gnant M, Reiner A, Rudas M, Pirc-Danoewinata H, Marosi C, Huber H, Drach J
Brit J Cancer 1995; 72: 51-55
50
3,449IF:
Cutaneous Side Effects in breast cancer patients treated with cytostatic polychemotherapy and rhGM-CSF: Immune henomena or drug toxicity ? (cutaneous reations to GM-CSF in breast cancer)
Locker G, Simonitsch I, Mader RM, Warlamides E, Gnant M, Jakesz R, Rainer H, Steger G
Breast Cancer Res Tr 1995; 34: 213-9
51
2,879IF:
Die Bedeutung der Lymphadenektomie bei Patienten mit colorectalem Carcinom
Jakesz R, Gnant M
Acta Chir Aust 1995; 9: 99
52
0,000IF:
Abdominalchirurgie in der geriatrischen Onkologie
Gnant M
Onko-logisch 1995; 3: 12-3
53
0,000IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 7 -
Platelet disorders in uraemia before and after haemodialysis under the influence of low dose apirin
Tschugguel W, Blaicher A, Klamer L, Felfernig M, Jungling G, Kurz M, Gnant M, Zimpfer M
Thromb Res 1995; 80: 225-33
54
1,443IF:
Kann man einer hochselektionierten Patientinnengruppe nach Brusterhaltender Therapie wegenMammakarzinoms die postoperative Nachbestrahlung ersparen?
Gruenberger T, Gorlitzer M, Soliman T, Rudas M, Mittlboeck M, Goetzinger P, Gnant M, Reiner A, Teleky B, Seitz W,Jakesz R
Acta Chir Aust 1995; 27: 269-73
55
0,000IF:
The importance of the effect of underlying disease on rejection outcomes following orthotopic livertransplantation
Berlakovich G, Imhof M, Karner-Hanusch J, Goetzinger P, Gollackner B, Gnant M, Hanelt S, Laufer G, Muehlbacher F,Steininger R
Transplantation 1996; 61: 554-60
56
3,544IF:
Neoadjuvant chemotherapy enables breast conserving surgery in patients with very large breastcancers
Taucher S, Gnant M, Djavanmard M, Kandioler D, Goetzinger P, Rudas M, Steger G, Jakesz R
Onkologie 1996; 19: 242-6
57
0,451IF:
Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors
Kandioler D, Dekan G, End A, Pasching E, Buchmayer H, Gnant M, Langmann F, Mannhalter C, Eckersberger F, Wolner E
J Thorac Cardiov Surg 1996; 111: 827-31
58
2,874IF:
Ovarian ablation in early breast cancer: overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
Lancet 1996; 348: 1189-1196
59
17,948IF:
Tumor recurrence after oLTX
Gruenberger T, Windhager T, Gnant M, Mittlboeck M, Steininger R, Herbst F, Muehlbacher F
Transplant Int 1996; 9S1: S151-4
60
1,522IF:
Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibiScintimammography
Helbich T, Becherer A, Trattnig S, Leitha T, Kelkar P, Seifert, Gnant M, Staudenherz A, Rudas M, Wolf G, Mostbeck GH
Radiology 1997; 202: 421-9
61
4,698IF:
p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situcarcinomas of the breast
Rudas M, Neumayer R, Gnant M, Mittlboeck, Jakesz R, Reiner A
Eur J Cancer 1997; 33: 39-44
62
2,743IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 8 -
Abgeschlossene und derzeit laufende adjuvante Therapieprotokolle bei Patientinnen mit operablemMammakarzinom (II)
Jakesz R, Gnant M, Schmid M, Smonigg H, Steindorfer P, Hausmaninger H, Sevelda P, Depisch D, Tausch C, Reiner G,Renner K, Stierer M, Pilz E, Jatzko G, Hofbauer F, Fridrik M, Schennach W, Dadak C, Haid A, Kusbista E, Scholz R,Sagaster P, Winter R, Lenzhofer R
Acta Chirurgica Austriaca 1997; 29: 62-67
63
0,000IF:
The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cellcarcinoma
Steger G, Gnant M, Djavanmard M, Mader R, Jakesz R, Pierce W, deKernion J, Figlin R, Belldegrun A
J Cancer Res Clin Oncol 1997; 123: 317-324
64
1,459IF:
5-fluorouracil kinetics in the interstital tumor space: clinical response in breast cancer patients
Müller M, Mader RM, Steiner B, Steger GG, Jansen B, Gnant M, Helbich T, Jakesz R, Eichler HG, Blöchl-Daum B
Cancer Res 1997; 57: 2598-601
65
8,426IF:
Protein-p53-Expression, Cell proliferation and steroid hormone receptors in Ductal Carcinoma in situof the breast
Reiner A, Rudas M, Neumayer R, Gnant M, Mittlboeck M, Jakesz R
Acta Chir Aust 1997; 29: 123-125
66
0,000IF:
It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancerpatients?
Gruenberger T, Gorlitzer M, Soliman T, Rudas M, Mittlboeck M, Gnant M, Reiner A, Teleky B, Seitz W, Jakesz R
Breast Cancer Res Tr 1998; 50: 37-46
67
2,430IF:
Evaluation of needle size for breast biopsy: Comparison of 14-, 16, and 18-gauge biopsy needles
Helbich T, Rudas M, Haitel A, Kohlberger P, Thurnher M, Gnant M, Wunderbaldinger P, Wolf G, Mostbeck G
Am J Roentgenol 1998; 171: 59-63
68
2,332IF:
Very low dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients
Jakesz R, Samonigg H, Gnant M, Kubista E, Steindorfer P, Hausmaninger H, Sevelda P, Tschurtschenthaler B, Fridrik M,Stierer M, Kolb R, Steger G, and the Austrian Breast Cancer Study Group
Eur J Cancer 1998; 34:66-70
69
2,743IF:
Tamoxifen for early breast cancer: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 1998; 351: 1451-1467
70
16,135IF:
Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellularcarcinoma after liver transplantation then albumin mRNA in peripheral blood
Peck-Radosavljevic M, Pidlich J, Bergmann M, Ferenci P, Seelos C, Wichlas M, Lipinski E, Gnant M, Gangl A, MuehlbacherF and the Liver Transplant Oncology Group
J Hepatol 1998; 28: 497-503
71
3,189IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 9 -
Outcomes of surgical, Percutaneous endoscopic, and percutaneous radiologic gastrostomies
Cosentini E, Sautner T, Gnant M, Winkelbauer F, Teleky B, Jakesz R
Arch Surg 1998; 133: 1076-1083
72
2,526IF:
In vivo tumors that overexpress Endothelial Monocyte-Activatin Polypeptide II demonstrateupregulation of tumor necrosis factor receptor p55 on tumor neovasculature
Wu P, Berger A, Huang J, Gnant M, Turner E, Alexander HR, Libutti S
Surg Forum 1998; 49: 436-438
73
0,000IF:
Polychemotherapy for early breast cancer: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 1998; 351: 1451-1467
74
11,793IF:
Neoadjuvante Chemotherapie bei Patientinnen mit Mammakarzinom
Jakesz R, Taucher S, Gnant M, Gebhard B, Kandioler D, Rudas M, Djavanmard M, Steger G
Zentralbl Chir 1998; 123 (S5) 147-150
75
0,425IF:
Die Wertigkeit der Stanzbiopsie in der Diagnostik palpabler Brusttumoren. Eine prospektive Analysean 150 Patienten.
Götzinger P, Gebhard B, Gnant M, Rudas M, Reiner A, Jakesz R
Chirurg 1998; 69: 1068-71
76
0,932IF:
Haemophilus parainfluenza liver abscess after successful liver transplantation
Friedl J, Stift A, Berlakovich G, Taucher S, Gnant M, Steininger R, Mühlbacher F
J Clin Microbiol 1998: 818-9
77
3,579IF:
Management of organ donation following trauma in conventional heart-beating donor and non-heart-beating donor situations
Pokorny H, Puhalla H, Krenn CG, Soliman T, Langer F, Gruenberger T, Gollackner B, Schindl M, Wamser P, Goetzinger P,Sautner T, Gnant M, Steininger R, Muehlbacher F
Trauma Care 1999; 9: 30-32
78
0,000IF:
Induction of Immunomediated Diseases by Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor During Cancer Treatment?
Locker GJ, Steger GG, Gnant M, Steiner B, Simonitsch I, Krainer M, Budinsky A, Brodowitz T, Jakesz R, Zielinski CC
J Immunotherapy 1999; 22: 85-9
79
3,059IF:
Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Geneand Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gene Expression andProlongation of Survival in Mice
Gnant M, Puhlmann M, Alexander HR, Bartlett DL
Cancer Res 1999; 59: 3396-3403
80
8,614IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 10 -
Indikationen und Kontraindikationen für brusterhaltende chirurgische Therapie
Jakesz R, Gebhard B, Gnant M, Taucher S
Chirurg 1999; 70: 394-399
81
0,932IF:
Regional versus Systemic Delivery of Recombinant Vaccinia Virus as Suicide Gene Therapy forMurine Liver Metastases
Gnant M, Puhlmann M, Bartlett DL, Alexander HR
Ann Surg 1999; 230: 352-361
82
5,987IF:
Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel andepidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)
Wenzel C, Schmidinger M, Locker GJ, Taucher S, Gnant M, Jakesz R, Steger GG
Wien Klin Wochenschr 1999; 111: 843-850
83
0,588IF:
Thymidine kinase-Deleted Vaccinia Virus Expressing Purine Nucleoside Phosphorylase as a Vectorfor Tumor-Directed Gene Therapy
Puhlmann M, Gnant M, Brown C, Alexander H, Bartlett D
Hum Gene Ther 1999; 10: 649-657
84
6,796IF:
Prognostic significance of mutations in the p53 gene, particularly in the Zinc-binding domains, inlymph node- and steroid receptor positive breast cancer patients
Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlboeck M, Fridrik M, Seifert M, Kubista E,Reiner A, Zeillinger R, Jakesz R, and the ABCSG
Eur J Cancer 1999; 35: 398-405
85
2,725IF:
Tumor-specific gene delivery using recombinant vaccinia virus in a lapine model of liver metastases
Gnant M, Noll L, Irvine K, Puhlmann M, Terrill R, Alexander R, Bartlett D
J Nat Cancer Inst 1999; 91:1744-50
86
14,159IF:
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive andlymph node-positive breast cancer
Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R,Stierer M, Fridrik M, Mlineritsch B, Mittlboeck M, Steger G, and the Austrian Breast Cancer Study Group
J Clin Oncol 1999; 17: 1701-1709
87
8,773IF:
Isolated hepatic perfusion for lapine liver metastases: Impact of hyperthermia on permeability oftumor neovasculature
Gnant M, Noll LA, Terrill RE, Wu PC, Berger AC, Nguyen HQ, Lans TE, Flynn BM, Libutti SK, Bartlett DL, Alexander HR
Surgery 1999; 126: 890-899
88
2,456IF:
In vivo sensitivity of human melanoma to tumor necrosis factor (TNF) alpha is determined by tumorproduction of the novel cytokine Endothelial-Monocyte Activating Polypeptide II (EMAPII)
Wu P, Alexander H, Huang J, Hwu P, Gnant M, Berger A, Turner E, Wilson O, Libutti S
Cancer Res 1999; 59: 205-12
89
8,614IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 11 -
Sensitiziation of tumor necrosis factor alpha (TNF) resistant human melanoma by tumor specific invivo transfer of the gene endcoding for Endothelial Monocyte Activating Peptide II (EMAP-II) usingrecombinant Vaccinia virus
Gnant M, Berger A, Huang J, Puhlmann M, Wu P, Merino M, Bartlett D, Alexander R, Libutti S
Cancer Res 1999; 59:4668-74
90
8,614IF:
Highlights vom ASCO 99 - Mammakarzinom adjuvant
Gnant M
Onkologisch 1999; 7: 9-11
91
0,000IF:
Class I major histocompatibiliy complex expression in human breast cancer correlates with nuclearlocalization of the 90 kDa heat shock protein
Gebhard B, Schuetz G, Ecker R, Steiner GE, Rudas M, Gnant M, Oehler R
Anticancer Res 1999; 19: 5293-5297
92
1,375IF:
Effects of hyperthermia and tumor necrosis factor on inflammatory cytokine secretion andprocoagulant activity in endocelial cells
Gnant M, Turner E, Alexander HR
Cytokine 2000; 12; 339-347
93
2,490IF:
TP53 Mutation and p53 Overexpression for Prediction of Response to Neoadjuvant Treatment inBreast Cancer Patients
Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlboeck M,Gnant M, Steger G, Jakesz R
Clin Cancer Res 2000; 6: 50-56
94
5,076IF:
Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase deletedmutant
Puhlmann M, Brown C, Gnant M, Huang J, Libutti S, Alexander H, Bartlett D
Cancer Gene Ther 2000; 7: 66-73
95
4,151IF:
Die chirurgische Axilladissektion: Technischer Standard oder obsolete Methode?
Bachleitner-Hofmann T, Gnant M
Zbl Chir 2000; 125: 822-829
96
0,302IF:
The angiogenesis inhibitor Endostatin does not affect murine cutaneous wound healing
Berger AC, Feldman AL, Gnant M, Kruger EA, Sim BKL, Hewitt S, Figg WD, Alexander HR, Libutti SK
J Surg Res 2000; 91: 26-31
97
1,674IF:
Favourable and unfavourable effects on long-term survival of radiotherapy for eraly breast cancer: anoverview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
Lancet 2000; 355:1757-1770
98
13,251IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 12 -
Die axilläre Lymphknotendissektion in der Therapie des Mammakarzinoms
Bachleitner-Hofmann T, Gnant M
Acta Chirurgica Austriaca 2000; 32: 119-123
99
0,000IF:
Adoptive zelluläre Immuntherapie
Stift A, Friedl J, Brostjan C, Dubsky P, Schueller G, Bachleitner-Hofmann T, Radelbauer K, Jakesz R, Gnant M
Acta Chirurgica Austriaca 2000; 32:255-259
100
0,000IF:
Tumor necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumorderived cytokine endothelial monocyte activating peptide II (EMAP-II)
Berger AC, Alexander HR, Wu PC, Tang G, Gnant M, Mixon A, Turner E, Libutti SK
Cytokine 2000; 12:992-1000
101
2,490IF:
Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes inhuman hepatocellular cancer
Friedl J, Stift A, Paolini P, Roth E, Steger GG, Mader R, Jakesz R, Gnant M
Cancer Biother Radio 2000; 15: 477-86
102
1,574IF:
Gentherapie - Tor zur Zukunft?
Bachleitner-Hofmann T, Gnant M
Acta Chirurgica Austriaca 2000; 32: 264-269
103
0,000IF:
Role of Tumor Necrosis Factor (TNF) on Toxicity and Cytokine Production after Isolated HepaticPerfusion
Lans TE, Bartlett DL, Libutti SK, Gnant M, Liewehr DJ, Venzon DJ, Turner EM, Alexander HR
Clin Cancer Res 2001; 7: 784-790
104
5,991IF:
Chirurgische Onkologie an der Jahrtausendwende - Editorial
Gnant M
Acta Chirurgica Austriaca 2000; 32: 249-250
105
0,000IF:
Different transendothelial migration behaviour pattern of blood monocytes derived from patients withbenign and malignant diseases of the breast
Gebhard B, Gnant M, Schutz G, Roka S, Weigel G, Kandioler D, Taucher S, Grunberger T, Roth E, Jakesz R, Spittler A
Anticancer Res 2000; 4599-604
106
1,416IF:
Heat Treatment of Hepatocellular Carcinoma Cells: Increased Levels of Heat Shock Proteins 70 and90 Correlate with Cellular Necrosis
Schueller G, Paolini P, Friedl J, Stift A, Dubsky P, Bachleitner-Hofmann T, Jakesz R, Gnant M
Anticancer Res 2001; 21: 295-300
107
1,416IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 13 -
Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients
Locker GJ, Wenzel C, Schmidinger M, Gnant M, Marosi C, Jakesz R, Zielinski CC, Steger G
Anticancer Drugs 2001; 12: 209-12
108
2,013IF:
Evaluation of the United States food and drug administration-approved scoring and test system ofHER-2 protein expression in breast cancer
Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-EckersbergerD, Gnant M, Jakesz R
Clin Cancer Res 2001; 7: 1669-1675
109
5,991IF:
Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer
Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R
Br Cancer Res Treat 2001; 67:1-8
110
2,866IF:
Prognostic Relevance of three histological grading methods in breast cancer
Latinovic L, Heinze G, Birner P, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Gnant M, Jakesz R, Oberhuber G,for the Austrian Breast and Colorectal Cancer Study Group
Int J Oncol 2001; 19: 1271-1277
111
2,330IF:
Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellularcarcinoma
Schmidinger M, Wenzel C, Locker GJ, Muehlbacher F, Steininger R, Gnant M, Crevenna R, Budinsky AC
Br J Cancer 2001; 85: 1850-1852
112
3,942IF:
Polychemotherapy for early breast cancer: an overview of the randomised trials with quality-adjustedsurvival analysis
Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A, for the EBCTCG
Lancet 1998; 358: 277-286
113
11,793IF:
Combined analysis of two phase II trials in patients wirh primary and advanced breast cancer withepidoxorubicin and docetaxel + G-CSF
Wenzel C, Locker GJ, Schmidinger M, Rudas M, Taucher S, Gnant MFX, Jakesz R, Steger GG
Anti-Cancer Drugs 2002; 13: 67-74
114
2,013IF:
Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma usingtumor lysate-pulsed dendritic cells
Bachleitner-Hofmann T, Stift A, Friedl J, Pfragner R, Radelbauer K, Dubsky P, Schueller G, Benkoe T, Niederle B, BrostjanC, Jakesz R, Gnant M
J Clin Endoc Metab 2002; 87: 1098-1104
115
5,447IF:
Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliativetreatment of patients with breast cancer
Wenzel C, Locker G, Pluschnig U, Zielinski C, Rudas M, Oberhuber G, Gnant M, Taucher S, Jakesz R, Steger G
Cancer Chemother Pharmacol 2002; 50: 155-159
116
2,170IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 14 -
Overexpression of hypoxia inducible factor (HIF) 1alpha ias associated with an unfavourableprognosis in lymph node-positive breast cancer
Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E Birner P,Oberhuber G
Clin Cancer Res 2002; 8: 1931-1837
117
5,991IF:
A Randomized Trial of Tamoxifen and Goserelin versus CMF: Evidence for the Superiority ofTreatment with Endocrine Blockade in Premenopausal Patients with Hormone-Responsive BreastCancer (ABCSG Trial 5)
Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Steger G,Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Wette V, for the Austrian Breast Cancer Study Group
J Clin Oncol 2002; 20: 1-9
118
9,868IF:
Induction of permeability across endothelial cel monolayers by tumor necrosis factor (TNF) accurs viaa tue factor-dependent mechanism: relationship between the procoagulant and permeability effects ofTNF.
Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EM, Gnant M, Alexander HR
Blood 2002; 100: 1334-1339
119
9,631IF:
Stereotactic 11-gauge vacuum assisted breast biopsy: a validation study
Pfarl G, Helbich TH, Riedl CC, Wagner T, Gnant M, Rudas M, Liberman L
AJR 2002; 179: 1503-1507
120
2,424IF:
Pattern of hormone receptor status of secondary contralateral breast cancers in patients receivingadjuvant tamoxifen
Bachleitner-Hofmann T, Gebhard B, Rudas M, Gnant M, Taucher S, Kandioler D, Janschek E, Dubsky P, Roka S, JakeszR
Clin Cancer Res 2002; 8: 3427-3432
121
5,991IF:
Young age as independent adverse prognostic factor in premenopausal patients with breast cancer
Dubsky PC, Gnant M, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B, Agstner I, Seifert M, Sevelda P, Jakesz R
Clin Breast Cancer 2002; 13: 67-74
122
0,000IF:
Dendritic cell based vaccination in solid organ cancer
Stift A, Friedl J, Brostjan C, Dubsky P, Bachleitner-Hofmann T, Jakesz R, Gnant M
J Clin Oncol 2003; 21: 135-142
123
10,864IF:
Sequential steroid hormone receptor measurements in primary breast cancer with and withoutintervening primary chemotherapy
Taucher S, Rudas M, Gnant M, Dubsky P, Roka S, Bachleitner-Hofmann T, Kandioler D, Wenzel C, Steger G, MittlboeckM, Jakesz R
Endo Rel Cancer 2003; 10: 91-98
124
8,894IF:
In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells
Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, Jakesz R, Gnant M
Int J Oncol 2003; 22: 651-660
125
2,536IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 15 -
Tamoxifen versus Tamoxifen plus Aminoglutethimid as Adjuvant Treatment in Postmenopausalbreast Cancer Patients wirth Hormone-responsive Disease: A Randomized Trial of 2,021 Patients(ABCSG Trial 6)
Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B,Steindorfer P, Kwasny W, Fridrik M, wette H, Hausmaninger H, for the Austrian Breast Cancer Study Group
J Clin Oncol 2003; 21: 984-990
126
10,864IF:
Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer
Schoppmann S, Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R, Birner
Int J Cancer 2003; 104: 677-682
127
4,375IF:
Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent foco-culture with tumor lysate pulsed dendritic cells
Schueller G, Stift A, Friedl J, Dugsky P, Bachleitner-Hofmann T, Benkoe T, Jakesz R, Gnant M
Int J Oncol 2003; 22: 1397-1402
128
2,536IF:
Impact of pretreatment thrombocytosis on survival in primary breast cancer
Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A,Jakesz R, for the Austrian Breast and colorectal Cancer Study Group
Thromb Haemost 2003; 89: 1098-1106
129
4,950IF:
Exact log rank tests for unequal follow-up
Heinze G, Gnant M, Schemper M
Biometrics 2003; 59: 1151-1157
130
1,324IF:
Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 andBRCA2 gene
Taucher S, Gnant M, Jakesz R
Langenbecks Arch Surg 2003; 388: 3-8
131
0,921IF:
Randomized trial: One cyle of anthracycline-containing adjuvant chemotherapy compared with sixcycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients
Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B,Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H, and the Austrian Breast and Colorectal Cancer StudyGroup
Onkologie 2003: 26: 115-119
132
1,154IF:
Gnant M, Dubsky P, Stift A, Friedl J, Steger G, Jakesz R, Zielinski C
Future Directions in the treatment of Breast Cancer: Celllular interventions using dendritic cells
Breast Canc Res Treatm 2003; 81
133
3,310IF:
Monitoring of circulating angiogenetic factors in dendritic cell-based cancer immunotherapy
Brostjan C, Bayer A, Zommer A, Gornikiewicz S, Roka S, Benkö T, Yaghubian R, Jakesz R, Steger G, Gnant M, Friedl J,Stift A
Cancer 2003; 98: 2291-30
134
4,017IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 16 -
The impact of progesterone receptor in prediction of complete pathological response to preoperativechemotherapy in primary breast cancer patients
Taucher S, Rudas M, Gnant M, Dubsky P, Sporn E, Roka S, Bachleitner-Hofmann T, Fitzal F, Kandioler D, Wenzel C,Steger G, Draxler W, Mittlboeck M, Jakesz R
European Surgery 2003;
135
0,000IF:
Pancreatic Cancer Treatment
Gnant M
European Surgery 2003; 35: 342-343
136
0,000IF:
Do we need HER2/neu testing for all patients with primary breast carcinoma?
Taucher S, Rudas M, Mader R, Gnant M, Dubsky P, Bachleitner-Hofmann T, Roka S, Fitzal F, Kandioler D, Sporn E, FriedlJ, Mittlboeck M, Jakesz R
Cancer 2003; 98: 2547-2553
137
4,017IF:
Consensus on Medical Treatment of Metastatic Breast Cancer
Beslija S, Bonneterre J, Burstein H, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler W, Krainer M, Menard S, MilesD, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, ZielinskiC, Zwierzina H
Br Canc Res Treatm 2003; 81: S1-S7
138
2,964IF:
Influence of neoadjuvant therapy with epirubicin an ddocetaxel on the expression of HER2/neu inpatients with breast cancer
Taucher S, Rudas M, Mader R, Gnant M, Sporn E, Dubsky P, Roka S, Bachleitner-Hofmann T, Fitzal F, Kandioler D,Wenzel C, Steger G, Mittlboeck M, Jakesz R
Breast Canc Res Treatm 2003; 82: 207-213
139
2,964IF:
Significant Increase in breast conservation in 16 years of clinical trials conducted by the AustrianBreast & Colorectal Cancer Study Group
Jakesz R, Hausmaninger H, Samonigg H, Gnant M, Kubista E, Depisch D, Kolb R, Mlineritsch B, Mischinger HJ, MenzelRC, Steindorfer P, Kwasny W, Tausch C, Stierer M, Seifert M, and the Austrian Breast & Colorectal Cancer Study Group(ABCSG)
Ann Surg 2003; 237: 556-564
140
6,664IF:
Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellularcarcinoma in vivo
Schueller G, Kettenbach J, Sedivy R, Stift A, Friedl J, Gnant M, Lammer J
Int J Oncol 2004; 24:609-13
141
3,056IF:
Gastrointestinal Autonomic Nerve Tumors: A surgical point of view
Stift A, Friedl J, Gnant M, Herbst F, Jakesz R, Wenzl E
World J Gastroenterology 2004; 10: 2447-2451
142
3,318IF:
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer
Schoppmann S, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M,Jakesz R, Horvat R, and the Austrian Breast and colorectal Cancer Study Group
Annals Surg 2004; 204: 306-312
143
5,907IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 17 -
Dendritic cell vaccination in medullary thyroid carcinoma
Stift A, Sachet M, Yagubian R, Bittermann C, Dubsky P, Pfragner R, Niederle B, Jakesz R, Gnant M, Friedl J
Clin Cancer Res 2004; 10:2944-2953
144
5,623IF:
Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325primary breast cancer patients
Taucher S, Rudas M, Mader R, Gnant M, Dubsky P, Roka S, Bachleitner-Hofmann T, Kandioler D, Steger G, Mittlboeck M,Jakesz R
Wien Klin Wochenschr 2004; 116:26-31
145
0,901IF:
Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primarybreast cancer: a pilot study
Wenzel C, Hussian D, Bartsch R, Pluschnig U, Locker GJ, Rudas M, Gnant M, Jakesz R, Zielinski C, Steger G
J Cancer Res Clin Oncol 2004; 130: 400-404
146
2,409IF:
Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation inan animal model
Schueller G, Kettenbach J, Sedivy R, Bergmeister H, Stift A, Friedl J, Gnant M, Lammer J
Oncology Rep 2004; 12: 495-499
147
1,356IF:
High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS
Roka S, Rudas M, Taucher S, Dubsky P, Bachleitner-Hofmann T, Kandioler D, Gnant M, Jakesz R
Eur J Surg Oncol 2004; 30; 243-247
148
1,882IF:
A prospective randomized trial to study the role of levamisole and interferon alfa in an adjuvanttheapy with 5-FU for stage-III colon cancer
Schippinger W, Jagoditsch M, Sorre C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, MischingerHJ, Hofbauer F, Holzberger P, Mittlböck M, Jakesz R, for the ABCSG
Br J Cancer 2005; 92: 1655-62
149
4,115IF:
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-yearsurvival: an overview of the randomised trials
Early Breast Cancer Trialists Collaborative Group (EBCTCG)
Lancet 2005; 365: 1687-1717
150
23,878IF:
Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellularcarcinoma treated by liver transplantation?
Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, Steininger R, Muehlbacher F
Am J Transplant 2005; 5: 788-94
151
6,002IF:
Preoperative chemotherapy with epidoxorubicin, docetaxel, and capecitabine plus pegfilgrastim inpatients with primary breast cancer
Wenzel C, Bartsch R, Locker GH, Hussian D, Pluschnig D, Sevelda U, Gnant M, Jakesz R, Zielinski C, Steger GG
Anticancer Drugs 2005; 16: 441-5
152
2,052IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 18 -
Medullary thyroid carcinoma: autologous tumor cell lins for dendritic cell vaccination
Pfragner R, Skofitsch G, Hoger H, Jech M, Rinner B, Siegl V, Niederle B, Gnant M, Friedl J, Stift A
Anticancer Res 2005; 25:4225-30
153
1,604IF:
Retroviral targeting of proliferating endothelial cells
Gornikiewicz A, Zommer A, Jakesz R, Gnant M, Brostjan C
Acta Biochim Pol 2005; 52: 731-5
154
1,863IF:
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozoleafter 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M,Gademann G, Kaufmann M, for the ABCSG and the GABG
Lancet 2005; 366: 455-62
155
23,887IF:
Inosine 5'-monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation andfunction of dendritic cells
Dubsky P, Friedl J, Stift A, Bachleitner-Hofmann T, Jakesz R, Gnant M, Weigel G
Clin Chim Acta 2006; 364: 139-47
156
2,328IF:
Bisphosphonates and the prevention of osteoporosis in the adjuvant setting
Gnant M
Breast Cancer Online 2005; Nov; 1-3, e55
157
0,000IF:
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C,Cameron D, Dowsett M, Barrios C, Steger G, Huang C, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H,Thomssen C, Lohrisch C, Suter T, Rüschoff J, Sütö T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci M, Gelber R,
N Eng J Med 2005; 353: 1659-72
158
44,016IF:
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centerexperience
Steger G, Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker G, Gnant M, Jakesz R, Zielinski C
Eur J Cancer 2005; 41: 2655-61
159
3,706IF:
Effects of radiotherapy and of differences in the extend of surgery for early breast cancer on localrecurrence and on 15-year survival: an overview of the randomised trials
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E,McGale P, McHugh T, Peto R, Taylor C, Wang Y and the Early Breast Cancer Trialists Collaborative Group (EBCTCG)
Lancet 2005; 366: 2087-106
160
23,878IF:
Preoperative second-line chemotherapy induces objective responses in primary breast cancer
Wenzel C, Locker G, Bartsch R, Pluschnig U, Hussian D, Zielinski CC, Rudas M, Gnant M, Jakesz R, Steger GG
Wien Klin Wochenschr 2005; 117: 48-52
161
0,901IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 19 -
Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients
Fitzal F, Sporn E, Draxler W, Mittlboeck M, Taucher S, Rudas M, Roedl O, Helbich T, Jakesz R, Gnant M
Breast Cancer Res Treatm 2006; 97: 9-15
162
4,671IF:
Aetiology and surgical management of toxic megacolon
Ausch C, Maddoff RD, Gnant M, Rosen HR, Garcia-Aguilar J, Hoelbling N, Herbst F, Buxhofer V, Holzer B, RothenbergerDA, Schiessel R
Int J Colorectal Disease 2006; 8: 195-201
163
2,006IF:
Surgical Oncology - a proud speciality
Gnant M
European Surgery 2006; 38/1: 2-3
164
0,000IF:
The endocrine origin and different characters of breast cancers - recent research on hormonereceptors and endocrine treatment
Dubsky P, Gnant M
Breast Care 2006; 1: 124-8
165
0,242IF:
VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact onlymphangiogenesis and survival
Schoppmann S, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvath R, Jakesz R, Birner P
Surgery 2006; 139: 839-46
166
2,977IF:
Management of bone loss induced by aromatase inhibitors
Gnant M
Cancer Invest 2006; 24: 328-30
167
2,335IF:
Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breastcancer
Schoppmann SF, Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, Horvat R, Jakesz R, Birner P
Breast Cancer Res Treat 2006; 99: 135-41
168
4,671IF:
Breast conservation: evolution of surgical strategies
Fitzal F, Gnant M
Breast 2006; 12S2: 165-73
169
1,705IF:
Breast Centers Revisited - a critical perspective
Gnant M
Breast Care 2006; 1: 150-1
170
0,242IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 20 -
Multidetector CT of Pancreas_ Effects of Contrast Material Flow Rate and Individualized Scan Delayon Enhancement of Pancreas and Tumor Contrast
Schueller G, Schima W, Schueller-Weidekamm C, Weber M, Stift A, Gnant M, Prokesch R
Radiology 2006; 241: 441-8
171
5,251IF:
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women withhormone-sensitive early-stage breast cancer: a meta-analysis
Gnant M, Jonat W, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R
Lancet Oncology 2006; 7: 991-996
172
10,119IF:
Heat shock treatment of tumor lysat-pusled DCs enhances their capacity to elicit antitumor T-cellresponses against medullary thyroid carcinoma
Bachleitner-Hofmann T, Strohschneider M, Krieger P, Sachet M, Dubsky P, Hayden H, Schoppmann S, Pfragner R, GnantM, Friedl J, Stift A
J Clin Endocrinol Metab 2006; 91: 4571-7
173
5,799IF:
Breast Cancer Chemoprevention - not yet there
Gnant M, Blaha P
Breast Care 2006; 1: 295-6
174
0,242IF:
A case of phylloides tumor with focal transition into low-grade lymphangiosarcoma
Bachleitner-Hofmann T, Schoppmann S, Rudas M, Birner P, Wiener H, Dubsky P, Blaha P, Sporn E, Panhofer P, Fitzal F,Roka S, Kandioler D, Gnant M, Jakesz R
Breast Care 2006; 1: 391-4
175
0,242IF:
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response followingneoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF
Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altoraj G, Zielinski CC, Lang A, Hais A, Jakesz R, Gnant M, Steger G
Br Canc Res Treat 2007; 104: 109-14
176
4,453IF:
Breast conserving surgery for T3/T4 breast cancer: an analysis of 196 patients
Fitzal F, Riedl O, Wutzl L, Draxler W, Rudas M, Pluschnig U, Handl-Zeller L, Dubsky P, Bachleitner-Hofmann T, Steger G,Jakesz R, Gnant M
Breast Cancer Res Treatm 2007; 103: 45-52
177
4,453IF:
Second Consensus on Medical Treatment of Metastatic Breast Cancer
Beslija S, Bonneterre J, Bustein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ, Krainer M,Menard S, Miles D, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, WilckenN, Wiltschke C, Zielinski C, Zwierzina H
Ann Oncol 2007; 18:215-25
178
4,875IF:
Zoledronic Acid effectively prevents Cancer treatment-induced bone loss in premnopausal womenreceiving adjuvant andocrine therapy for hormone responsive breast cancer
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC,Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, and the ABCSG
J Clin Oncol 2007; 25: 820-8
179
15,484IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 21 -
Pathologic complete response with 6 vs. 3 cycles oof Neoadjuvant epirubicin/decetaxel + G-CSF inoperable breast cancer: resutls of ABCSG-14
Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer C, Haid A,Poestlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R, and the ABCSG
J Clin Oncol 2007; 25: 2012-8
180
15,678IF:
The use of a breast symmetry index for objective evaluation of breastcosmesis
Fitzal F, Krois W, Trischler H, Wutzel L, Riedl O, Kühbelböck U, Wintersteiner B, Cardoso MJ, Dubsky P, Gnant M, JakeszR, Wild T
Breast 2007;4:429-35
181
1,739IF:
Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated withpoor outcome in node-negative breast cancer
Schindl M, Gnant M, Schoppmann S, Horvat R, Birner P
Anticancer Res 2007; 27: 949-52
182
1,414IF:
Managing aromatase inhibitor-associated bone loss in breast cancer
Lipton A, Gnant M, Aapro M
Womans Health 2007; 3:441-448
183
0,000IF:
Extended adjuvant therapy with Anastrozole among postmenopausal breast cancer patients: Resultsfrom the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K,Dadak C, Ruecklinger E, Samonigg H, on behalf of the ABCSG
J Natl Canc Inst 2007; 99:1845-53
184
15,678IF:
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausalpatients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data fromrandomised adjuvant trials
LHRH-agonists in Early Breast Cancer Overview Group
Lancet 2007; 369: 1711-23
185
28,638IF:
Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial
Suter T, Procter M, van Veldhuisen D, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn J,Ageev F, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber R, Piccart-Gebhart M
J Clin Oncol 2007; 25:3859-65
186
15,484IF:
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women withfavourable early breast cancer
Poetter R, Gnant M, Kwasny W, Tausch C, Handl-Zeller L, Pakisch B, Taucher S, Hammer J, Luschin-Ebengreuth G,Schmid M, Sedlmayer F, Stierer M, Reiner G, Kapp K, Hofbauer F, Rottenfusser A, Poestlberger S, Haider K, Draxler W,Jakesz R; on behaslf of the ABCSG
Int J Radiat Oncol 2007; 68: 334-40
187
4,290IF:
Novel strategies in oncoplastic surgery for breast cancer: immediate partial reconstruction of breastdefects
Fitzal F, Nehrer G, Deutinger M, Jakesz R, Gnant M
Eur Surg 2007; 39:330-39
188
0,000IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 22 -
Capecitabine and Trastuzumab in heavily preatreated patients with metastatic breast Cancer
Bartsch G, Wenzel C, Altoraj F, Pluschnig U, Rudas M, Mader R, Gnant M, Zielinski C, Steger G
J Clin Oncol 2007; 25: 3853-8
189
15,484IF:
An oncoplastic procedure for central and medio-cranial breast cancer
Fitzal F, Nehrer G, Hoch D, Riedl O, Gutharc S, Deutinger M, Jakesz R, Gnant M
Eur J Surg Oncol 2007; 33: 1158-63
190
3,917IF:
HER-2 and progesterone receptor are not predictive of response to fulvestrant treatment
Bartsch T, Wenzel C, Altrofaj G, Pluschnig U, Mader R, Gnant M, Jakesz R, Rudas M, Zielinski C, Steger G
Clin Cancer Res 2007; 13: 4435-9
191
6,250IF:
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: arandomised controlled trial
Smith I, Procter M, Gelber R, Guillaume S, Teyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J,Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardlay A, Harbeck N, Lopez R, Mallmann P, Gelmon K, WilckenN, Wist E, Rovira P, Piccart-Gebhart M, for the HERA study team
Lancet 2007; 369: 29-36
192
28,638IF:
A prospective randomized phase III trial of adjuvant chemotherapy with 5-fuorouracil and leucovorinin patients with stage II colon cancer
Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thodtmann R, Tschmelitsch J, Jagoditsch M, Steger G, Jakesz R,Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, for the ABCSG
Br J Cancer 2007; 97(8):1021-7
193
4,635IF:
Allogenic tumor lysate can serve as both antigen source and protein supplementation for dendriticcell culture
Dubsky P, Hayder H, Sachet M, Bachleitner-Hofmann T, Hassler M, Pfragner R, Gnant M, Stift A, Friedl J
Cancer Immunol Immunother 2008;57(6):859-70
194
3,728IF:
The potential risk of neoadjuvant chemotherapy in breast cancer patients - results from a prospectiverandomised trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)
Taucher S, Steger G, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Bartsch R, Dubsky P,Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M
Breast Cancer Res Treatm 2008; 112: 309-16
195
4,453IF:
Guidance on the use of bisphosphonates in solid tumours: recommendations of an internationalexpert panel
Aapro M, Abrahamsson P, Body J, Coleman R, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J, Hadji P,Hortobagyi G, Jonat W, Lipton A, Monnier A, Paterson A, Rizzoli R, Saad F, Thuerlimann B
Annals of Oncology 2008; 19: 420-32
196
4,875IF:
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastaticbreast cancer
Bartsch R, Welzel C, Gampenrieder S, Pluschnig U, Altoraj G, Rudas M, Mader R, Dubsky P, Rottenfusser A, Gnant M,Zielinski C, Steger G
Cancer Chemother Pharmacol 2008; 62: 903-10
197
2,568IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 23 -
Low telomerase activity: possible role in the progression of human medullary thyroid carcinoma
Stadler G, Wieser M, Streubel B, Stift A, Friedl J, Gnant M, Niederle B, Katinger H, Pfragner R, Grillari J, Voglauer R
Eur J Cancer 2008; 44: 866-75
198
4,454IF:
Cyclin D1 expression in breast cancer and tamoxifen therapy
Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, GrillR, Stierer M, Gnant M, Filipits M, for the ABCSG
Clin Cancer Res 2008; 14: 1767-74
199
6,250IF:
The localization of small tumor deposits in the SLN predicts Non-SLN macrometastases in breastcancer patients
Li J, Haensch W, Rudas M, Kemmer W, Warnick P, Fischer J, Gnant M, Schlag PM, Bembenek A
Eur J Surg Oncol 2008; 34: 857-862
200
3,917IF:
Adjuvant chemotherapy in oestrogen-receptor-poor early breast cancer: patient-level meta-analysisof randomised trials
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Lancet 2008; 371: 29-40
201
28,638IF:
Exemestane as primary systemic treatment for hormone receptor positive postmenopausal breastcancer patients: a phase II trial opf the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)
Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, UrbaniaA, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R, on behalf of the ABCSG
Breast Cancer Res Treat 2008; 112: 203-213
202
4,453IF:
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primarybreast cancer patients receiving adjuvant CMF chemotherapy
Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Desnison U, Mlineritsch B, Steger G, KwansyW, Stoeger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Poetter R, Gnant M
Clin Cancer Res 2008; 14: 2082-7.
203
6,250IF:
Moderne Tumortherapie des Pankreaskarzinoms
Sahora K, Trenkwitz D, Akan B, Kuehrer I, Goetzinger P, Gnant M
J Gastroenterol Hepatol Erkr 2008; 6: 17-24
204
0,000IF:
Is risk of central nervous system (CNS)-relaps related to adjuvant taxane treatment in node-positivebreast cancer? Results of the CNS-substudy in the Intergroup phase III BIG 02-98 trial
Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M, Nordenskjöld B,Gnant M, Gutierrez J, Lang I, Crown JPA, Piccart-Gebhart M, on behalf of the BIG 02-98 Collaborative Group
Ann Oncol 2008; 19: 1837-41
205
5,179IF:
Neoadjuvante Therapie des Pankreaskarzinoms
Sahora K, Akan B, Kuehrer I, Goetzinger P, Gnant M
Wien Klin Wochenschr 2008; 3: 6-9
206
0,885IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 24 -
(Neo-)Adjuvant Chemotherapy in Breast Cancer - Trials, errors and new Rationales from the SABCS2007
Dubsky P, Gnant M
memo 2008; 1: 23-36
207
0,000IF:
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breastcancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kaessmann H, Piswanger-Soelkner C, Seifert M,Schippinger W, Menzel C, Dubsky P, Fitzal F, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Jakesz R, on behalf ofthe ABCSG
Lancet Oncology 2008; 9:840-9.
208
12,274IF:
Breast-conserving therapy for centrally located breast cancer
Fitzal F, Mittlboeck M, Trischler H, Krois W, Nehrer G, Deutinger M, Jakesz R, Gnant M
Ann Surg 2008; 247: 470-6
209
7,446IF:
Adjuvant endocrine Therapy in premenopausal women with breast cancer
Gnant M, Dubsky P, Fitzal F, Steger G, Jakesz R
Breast Care 2008; 3: 311-6
210
0,242IF:
Einsatz von Erythropoease-stimulierenden Proteinen bei anämischen Patienten mit malignenErkrankungen
Ludwig H, Auberger T, Burghuber O, Gnant M, Hopfinger G, Jaeger U, Keil F, Kornek G, Linkesch W, Petrau E, Pirker R,Pittermann E, Reinthaller A, Samonigg H, Steger G, Stockenhuber F, Studnicky M, Weiss G, Zielinski C
Wien Klin Wochenschr 2008; 120: 507-13
211
1,000IF:
Adjuvant endocrine therapy plus zoledronic acid in premenopausal breast cancer
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Poestlberger S, Menzel C, Jakesz R, Kubista E, Marth C,Greil R, on Behalf of the ABCSG
New Engl J Med 2009; 360:679-91
212
52,589IF:
Intraoperative frozen section analysis for breast conservingt therapy in 1.016 patients with breastcancer
Riedl O, Fitzal F, Mader N, Dubsky P, Rudas M, Mittlboeck M, Gnant M, Jakesz R
Eur J Surg Oncol 2009; 35: 264-70
213
3,917IF:
To measure the unmeasurable
Gnant M
World J Surgery 2009; 33: 52-3
214
2,696IF:
Incomplete surgical resection of DCIS results in activation of HER-2 in residual breast cancer cells
Singer C, Hudelist G, Fuchs E, Koestler W, Fink-Retter A, Gschwantler-Kaulich D, Gnant M, Rudas M, Czerwenka K,Kubista E
Endocrine Rel Cancer 2009; 16: 73-83
215
5,193IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 25 -
The evolving role of Zoledronic Acid in early breast cancer
Gnant M
OncoTargets and Therapy 2009; 2: 95-104
216
IF:
Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines inpatients with metastatic medullary thyroid carcinoma
Bachleitner-Hofmann T, Friedl J, Hassler M, Hayden H, Dubsky P, Sachet M, Rieder E, Pfragner R,Brostjan C, Riss S, Niederle B, Gnant M, Stift A
Oncol Rep. 2009; 21:1585-92
217
1,588IF:
Pankreaskarzinom und periampulläres Karzinom
Sahora K, Kührer I, Trenkwitz D, Friedl J, Sautner T, Goetzinger P, Gnant M
J Gastroenterol Hepatol Erkr 2009; 7: 36-46
218
0,669IF:
Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendriticcells for dendritic cell based immunotherapy
Hayden H, Fridl J, Dettke M, Sachet M, Hassler M, Dubsky P, Bachleitner-Hofmann T, Gnant M, Stift A
J Immunoth 2009; 32: 658-64
219
3,203IF:
Breast cancer chemoprevention - a vision not yet realised
Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Steger G, Jakesz R, Gnant M
Eur J Cancer Care 2009; 18; 438-46
220
1,038IF:
Bisphosphonates as adjuvant treatment for breast cancer
Gnant M, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Exner R, Blaha P, Jakesz R, Schippinger W, Greil R
Curr Breast Canc Rep 2009; 1: 54-63
221
IF:
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant inpostmenopausal patients with metastatic breast cancer
Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, PoberM, Zielinski CC, Steger GG; on behalf of the Austrian Fulvestrant Registry.
Breast Cancer Res Treat 2009; 115: 373-80
222
4,453IF:
Is endocrine Therapy really pleasant? Considerations about the long-term use of antihormonaltherapy and its benefit/side effect ratio
Blaha P, Exner R, Dal Borgo A, Bigenzahn S, Panhofer P, Riedl O, Schoppmann S, Bachleitner-Hofmann T, Sporn E,Pluschnig U, Fitzal F, Steger G, Jakesz R, Dubsky P, Gnant M
Breast Care 2009; 4:155-61
223
0,500IF:
New results from the use of bisphosphonates in cancer patients.
Coleman R, Gnant M
Curr Opin Support Palliat Care 2009; 3: 213-8
224
2,073IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 26 -
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primarytherapy of early breast cancer 2009.
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members.
Ann Oncol 2009; 20:1319-29
225
5,647IF:
Third Consensus on Medical Treatment of Metastatic Breast Cancer
Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M,Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C,Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H; for the Central European Cooperative Oncology Group
Ann Oncol 2009; 20: 1771-85
226
5,647IF:
Maintaining Bone Density in patients undergoing treatment for breast cancer: is there an adjuvantbenefit?
Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann SF, Steger G, Marth C, Samonigg H, Huettner K, Fohler H,Ruecklinger E, Jakesz R, Greil R, on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)
Clin Breast Cancer 2009; 9: s18-27
227
2,065IF:
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positivebreast cancer patients receiving adjuvant tamoxifen therapy
Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W,Nader A, Stierer M, Gnant M
Clin Cancer Res 2009; 15: 5888-94
228
6,747IF:
Bisphosphonates in the prevention of disease recurrence: Current results and ongoing trials
Gnant M
Curr Cancer Drug Targets 2009; 9: 824-33
229
5,385IF:
Cystic neoplasms of the pancreas: Conservative or operative treatment?
Akan B, Sahora K, Puhalla H, Gnant M, Jakesz R, Goetzinger P
Eur Surg 2009; 40:220-6
230
0,629IF:
Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?
Gnant M, Blaha P, Dubsky P, Exner R, Fitzal F, Sporn E, Panhofer P, DalBorgo A, Bigenzahn S, Jakesz R, Steger G
Ther Adv Med Oncol 2009; 1: 123-36
231
IF:
Adjuvant endocrine therapy in premenopausal women with breast cancer
Gnant M
BCO 2009; 12 (5): 1-8 (e8)
232
0,000IF:
Predicting for activity of second-line trastuzumab-based therapy in HER2-positive advanced breastcancer
Bartsch R, DeVries C, Pluschnig U, Dubsky P, Horvath Z, Gampenrieder S, Rudas M, Mader R, Rottenfusser A, WiltschkeC, Gnant M, Zielinski CC, Steger GG
Br J Cancer 2009; 9: 367
233
4,346IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 27 -
Fighting overtreatment in adjuvant breast cancer therapy
Gnant M, Steger GG
Lancet 2009; 374: 2029-30
234
30,758IF:
Bisphosphonates in the adjuvant treatment of early breast cancer
Gnant M
Breast Cancer Res 2009; 11: S17
235
4,696IF:
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleaoni M, Coombes C,Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R, for the Aromatase InhibitorOverview Group
J Clin Oncol 2010; 28: 509-18
236
18,970IF:
Local-Regional Treatment of Primary Breast Cancer: Consensus Recommendation from anInternational Expert Panel
Kaufmann M, von Mickwitz G, Morrow M, The Biedenkopf Expert Panel Members
Cancer 2010; 116: 1184-9
237
5,131IF:
The anti-tumor effect of bisphosphonates: ABCSG-12, ZO-FAST and more...
Gnant M, Eidtmann H
Crit Rev Onc Hem 2010; 74: S2-6
238
4,589IF:
Mammakarzinom: Bisphosphonate in der Adjuvanz - auch aus gesundheitsökonomischer Sicht einesinnvolle Therapie
Lux MP, Nowitzki C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann M
Geburtsh Frauenheilk 2010; 70: 8-11
239
0,342IF:
Cost-Effectiveness of Zoledronic Acid Plus Endocrine Therapy in Premenopausal Women withHormone-Responsive Early Breast Cancer
Delea T, Taneja C, Sofrygin O, Kaura S, Gnant M
Clin Breast Cancer 2010; 4: 267-74
240
2,790IF:
The evolution of bone-targeted therapies: Introduction
Gnant M
Sem Oncol 2010; 37: S1
241
3,355IF:
Results of the Zometa® Cost-utility model for the German healthcare system based omn the resultsof the ABCSG-12 study
Lux MP, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann M
Onkologie 2010; 33: 360-8
242
1,153IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 28 -
Neue Studiendaten zur endokrinen Langzeittherapie
Gnant M
Gyn Spectrum 2010; 1: 4-6
243
0,000IF:
Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vitroprocesses
Starlinger P, Moll H, Assinger A, Nemeth C, Gruenberger B, Gruenberger T, Kuehrer I, Schoppmann S, Gnant M, BrostjanC
J Thromb Hemosta 2010; 8: 1809-19
244
4,701IF:
Can oral bisphophonates really reduce the risk of breast cancer in healthy women?
Gnant M
J Clin Oncol 2010; 28: 3548-51
245
18,970IF:
Capecitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced andmetastatic breast cancer
Gampenrieder S, Bartsch R, Scheuer R, Pluschnig U, Dubsky P, Gnant M, Zielinski C, Steger G
Breast Care 2010; 5: 158-162
246
0,364IF:
Neoadjuvant Treatment and Breast Conserving Surgery - a success of clinical research in breastcancer
Gnant M
Wien Med Wochenschr 2010; 160: 163-6
247
0,000IF:
Overview of the ransomized trials of radiotherapy in ductal carcinoma in situ of the breast
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C,Peto R, Bijker N, Solin L, Darby S
J Natl Cancer Inst Monogr 2010; 41: 162-77
248
14,697IF:
Closing in on the unknown enemy
Gnant M, Dubsky PC
Lancet Oncol 2010; 11:402-3
249
17,764IF:
Breast Cancer: Rank Ligand Inhibition
Bartsch R, Steger G, Gnant M, Ziebermayr R
Breast Care 2010; 5: 320-325
250
0,364IF:
HER-2/neu-expression correlates with vascular endothelial growth factor-C and lymphangiogenesisin llymph node positive breast cancer
Schoppmann S,Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, Dubsky P, Gnant M, Jakesz R, Birner P
Ann Oncol 2010; 21: 955-60
251
6,452IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 29 -
Potential anticancer properties of bisphosphonates
Neville-Webbe H, Gnant M, Coleman R
Semin Oncol 2010; 7: S53-65
252
3,355IF:
Use of aromatase inhibitors and bisphosphonates as an anti-cancer therapy in postmenopausalbreast cancer
Mouridsen H, Lonning P, Beckmann M, Blackwell K, Doughty J, Gligorov J, Llombart-Cussac A, Robidoux A, Thürlimann B,Gnant M
Expert Rev Anticancer Ther 2010; 11: 1825-36
253
2,976IF:
Prevention of bone metastases and management of bone health in early breast cancer
Gnant M, Hadji P
Breast Cancer Research 2010; 12: 216
254
4,859IF:
Modulation of plasma complement by the initial dose of epirubicin / docetaxwl therapy in breastcancer and its predictive value
Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-DeschmannM , Rech-Weichselbraun I, Burghuber C,Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R
Br J Cancer 2010; 103: 1201-8
255
4,831IF:
10 years of ATAC: one question answered, many others unresolved
Gnant M
Lancet Oncology 2010; 11: 1109-10
256
17,764IF:
Adjuvant Bisphosphonate therapy in postmenopausal breast cancer patients
Gnant M
Breast Care 2010; 5: 298-304
257
0,364IF:
Dosing of Zoledronic Acid throughout the treatment continuum in breast cancer
Hadji P, Gnant M, Aapro M, Lipton A, Coleman R
Crit Rev Oncol Hematol 2011; 79:175-88
258
4,411IF:
Sentinel Node Biopsy after primary chemotherapy in breast cancer: A note of caution from resultsfrom ABCSG-14
Tausch C, Steger G, Haid A, Jakesz R, Fridrik M, Reitsamer R, Poestlberger S, Lang A, Gnant M, Greil R, on behalf of theABCSG
Breast J 2011; 17: 230-8
259
1,643IF:
Adjuvant Zoledronic Acid reduces disease recurrence in breast cancer:Antitumor effects on the seed and the soil
Gnant M
Curr Cancer Ther Rev 2011; 7: 111-18
260
IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 30 -
Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy betweenchemotherapy and anti-VEGF treatment
Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann S, Gnant M, Brostjan C
Neoplasia 2011; 13; 5: 419-27
261
5,946IF:
Lipoxigenase mediates Invasion of intrametastatic lymphatic vessels and propagates lymph nodemetastasis of human mammary carcinoma xenografts in mouse
Kerjaschki D, Bago-Horvath Z, Rudas M, Sexl V, Wolbank S, Schneckenleithner C, Wolbank S, Bartel G, Krieger S, Kalt R,Hantusch B, Keller T, Nagy-Bojarski K, Huttary N, Raab I, Lackner K, Krautgasser K, Schachner H, Kaserer K, Rezar S,Madlener S, Vonach C, Davidovits A, Nosaka H, Haemmerle M, Viola K, Dolznig H, Schreiber M, Nader A, Mikulits W,
J Clin Invest 2011; 132: 2000-12
262
13,069IF:
NeoGemTax - Gemcitabine and docetaxel as neoadjuvant treatment for locally advanced non-metatasized pancreatic cancer
Sahora K, Kuehrer I, Fitzal F, Schindl M, Koelblinger C, Goetzinger P, Gnant M
World J Surg 2011; 35: 1580-9
263
2,362IF:
Intravenous bisphosphonates for breast cancer: Impact on patient outcomes and scientific concepts
Gnant M
Breast Disease 2011; 33: 71-81
264
IF:
Platelet-stored angiogenesis factors: Clinical monitoring is prone to artifacts
Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, Schoppmann S, Gnant M, Brostjan C
Disease Markers 2011; 31: 55-65
265
1,642IF:
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early breast cancer:62-month follow-up from ABCSG-12
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengruth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G,Bauernhofer T, Eidtmann H, Eiermann W., Steger G, Kwasny W, Dubsky P, Hochreiner G,, Forsthuber EP, Fesl C, Greil R,on behalf of the ABCSG
Lancet Oncol 2011; 12: 631-41
266
22,589IF:
A new molecular predictor of distant recurrence in estrogen recpetor-positive HER2-negative breastcancer adds independent information to conventional clinical risk factors
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer C, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V,Jänicke F, Schmidt M, Kölbl H, Rody A, kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS,Henning G, Gehrmann M, Gnant M
Clin Cancer Res 2011; 17: 6012-20
267
7,742IF:
Zoledronic Acid in Breast Cancer: Latest Findings and Interpretations
Gnant M
Ther Adv Med Oncol 2011; 3: 293-301
268
IF:
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thuerlimann B, Senn HJ, & Panel members
Ann Oncol 2011; 22: 1736-47
269
6,425IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 31 -
St. Gallen 2011: Summary of the consensus discussion
Gnant M, Harbeck N, Thomssen C
Breast Care 2011; 6: 136-41
270
0,446IF:
Oncologic safety of breast conserving surgery after tumor downsizing by neoadjuvant therapy: Aretrospective single centre cohort study
Fitzal F, Riedl O, Mittlboeck M, Dubsky P, Bartsch R, Steger G, Jakesz R, Gnant M
Breast Cancer Res Treatm 2011; 127: 121-128
271
4,431IF:
Preoperative oxaliplatin, capecitabine and external beam readiotherapy in patients with newlydiagnosed, primary operable, cT3NxM0 low rectal cancer - a Phase II study
Öfner D, DeVries A, Schaberl-Mosef R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp K, Fastner G, Keil F, Eisterer W,Jäger R, Offner F, Gnant M, Thaler J, for the TAKO 05/!BCSG R02 Trial Investigators
Strahlenther Oncol 2011; 187: 100-7
272
3,561IF:
Relevance of breast hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet 2011; 378: 771-84
273
38,278IF:
Developing an international network for breast cancer research: the Breast International Group (BIG)experience
Gnant M, Piccart-Gebhart M, Goldhirsch A, Baselga J, Cameron D, Di Leo A, Dowsett M, Gelber M, von Mickwitz G,Wadvogel C, Straehle C
Clin Invest 2011; 1(5): 623-28
274
13,069IF:
Discrimination between circulating endothelial cells and blood cell populations with overlappingphenotype reveals distinct regulation and predictive potential in cancer therapy
Starlinger P, Brugger P, Reiter C, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann S, Gnant M, Brostjan C
Neoplasia 2011; 13: 980-90
275
5,946IF:
Impact of Body Mass Index on the efficacy of endocrine therapy in premenopausal patients withbreast cancer: An analysis of the prospective ABCSG-12 trial
Pfeiler G, Koenigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer C, Poestlberger S, Steger G, Seifert M, Dubsky P,Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M
J Clin Oncol 2011; 29: 2653-9
276
18,372IF:
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breastcancer: Practical guidance for prevention and treatment
Hadji P, Aapro M, Body J, Bundred N, Brufsky A, Coleman R, Gnant M, Guise T, Lipton A
Annals of Oncology 2011; 22: 2546-55
277
6,425IF:
Targeted therapies: Adjuvant bisphosphonates - an option with low estrogen?
Gnant M
Nature Reviews Clinical Oncology 2011; 8: 698-9
278
11,963IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 32 -
Pregnancy after breast cancer: if you wish, ma'am
Pagani O, Partridge A, Korde L, Badve S, Bartlett J, Albain K, Gelber R, Goldhirsch A; Breast International Group; NorthAmerican Breast Cancer Group Endocrine Working Group
Breast Cancer Res Treatm 2011; 129: 309-17
279
4,431IF:
NeoGemOx - Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced non-metastasized pancreatic cancer
Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, Teleky B, Jakesz R, Pecl-Radosavlejvid M,Ba'ssalamah A, Zielinski C, Gnant M
Surgery 2011; 143: 311-20
280
3,103IF:
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breastcancer mortality in women with early breast cancer: analysis of individual patient data on 10,801women in 17 randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet 2011; 378: 1707-16
281
38,278IF:
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausalwomen with low proliferating breast cancer
Bago-Horvath Z, Rudas M, Dubsky P, Singer C, Dietze O, Greil R, Jelen A, Boehm G, Jasarevic Z, Lang A, Gruber C,Poestlberger S, Filipits M, Gnant M, on behalf of the ABCSG
Clin Cancer Res 2011;17: 7828-34
282
7,742IF:
Bisphosphonates in the adjuvant treatment of breast cancer - Rationale and clinical data
Gnant M
Clin Invest 2011; 1: 97-107
283
13,069IF:
Impact of anti-HER2 therapy on overall survival in HER2-positive metastatic breast cancer patientswith brain metastases
Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, DieckmannK, Mader R, Gnant M, Zielinski C, Steger G
Br J Cancer 2012; 106: 25-31
284
5,082IF:
Dual HER2 inhibition in breast cancer treatment
Gnant M, Steger GG
Lancet 2012; 379; 596-8
285
39,060IF:
Results of the first Austrian multidisciplinary expert panel on controversies in local treatment of breastcancer
Knauer M, Gnant M, Fitzal F, Panel Members
Breast Care 2012; 7: 61-66
286
0,680IF:
Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, andLymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast andColorectal Cancer Study Group (ABCSG)
Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, GnantM
Ann Surg Oncol 2012; 19: 1808-17
287
4,166IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 33 -
Zoledronic Acid in the treatment of early stage breast cancer: Is there a final verdict?
Gnant M
Curr Oncol Reports 2012; 14:35–43
288
3,327IF:
Recommendations from an International Consensus Conference on the Current Status and Future ofNeoadjuvant Systemic Therapy in Primary Breast Cancer
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M,Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L
Ann Surg Oncol 2012; 19: 1508-16
289
4,166IF:
Antiresorptive treatment options and bone health in cancer patients - safety profile and clinicalconsiderations
Hadji P, Aapro M, Costa L, Gnant M
Cancer Treatm Rev 2012; 38, 815-24
290
6,054IF:
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
Baselga J, Campone M, Piccart M, Burris HA, Rugo, HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, BeckJT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu C, Mukhopadhyay P, Lebwohl D, Hortobagyi GN
N Eng J Med 2012; 366: 520-9
291
53,298IF:
Objetively measured breast symmetry has no influence on quality of life in breast cancer patients
Exner R, Krois W, Mittlböck M, Dubsky P, Jakesz R, Gnant M, Fitzal F
Eur J Surg Oncol 2012; 38: 130-6
292
2,614IF:
Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locallyadvanced rectal cancer - A two stage phase II clinical trial
Resch G, DeVries A, Oefner D, Eisterer W, Rabl H, Jagoditsch M, Gnant M, Thaler J, on behalb of the ABCSG
Radiother Oncol 2012; 102: 10-3
293
5,580IF:
Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?
Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise T, Lipton A, Aapro MS
Cancer Treatm Rev 2012; 38: 798-806
294
6,054IF:
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analysesof long-term outcome among 100 000 women in 123 randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet 2012; 379: 432-44
295
39,060IF:
Bisphosphonates: prevention of bone metastases in breast cancer
Gnant M, Dubsky P, Hadji P
Recent Results Cancer Res. 2012;192:65-91
296
2,000IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 34 -
The sequential use of endocrine treatment for advanced breast cancer: where are we?
Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Guzudar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C,Robertson J
Ann Oncol 2012; 23: 1378-86
297
7,384IF:
Neoadjuvant chemotherapy increases the rate of breast conservation on lobular-type breast cancerpatients
Fitzal F, Mittlboeck M, Steger G, Bartsch G, Rudas M, Dubsky P, Riedl O, Jakesz R, Gnant M
Ann Surg Oncol 2012; 19: 519-26
298
4,166IF:
Taxoxifen and Anastrozole as a sequencing strategy: A randomized controlled trial inpostmenopausal patients with endocrine-responsive early breast cancer: Final results from theAustrian Breast and Colorectal Cancer Study Group
Dubsky P, Jakesz R, Mlineritsch B, Poestlberger, Graz2, Kwasny W, Tausch C, Samonigg H, Haider K, Fitzal F, Singer C,Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger G, Greil R, Filipcic L, Gnant M, onbehalf of the ABCSG
J Clin Oncol 2012; 30: 722-8
299
18,372IF:
Anticancer activity of bisphosphonates in breast cancer
Gnant M
Anticancer Agents Med Chem 2012; 12: 114-22
300
3,144IF:
Brain metastases free survival differs between breast cancer subtypes
Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F,Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.
Br J Cancer 2012; 106: 440-6
301
5,082IF:
Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasivebreast cancer
Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Fitzal F, Dubsky P, Jesch B, Birner P
Breast Cancer Res Treatm 2012; 134: 237-44
302
4,469IF:
Treatment of bone metastases in patients with advanced breast cancer
Gnant M, Balic M, Petru E, Raunik W, Singer CF, Steger GG, Watzke IM, Brodowicz T
Breast Care 2012; 7: 92-8
303
0,680IF:
Bone Targeted Agents: Effects on disease progression and mortality in solid tumour andhaematological cancers
Coleman RE, Gnant M, Morgan G, Clezardin P
J Nat Cancer Inst 2012; 104: 1059-1067
304
14,700IF:
Overcoming endocrine resistance in breast cancer: importance of mammalian target of rapamycin(mTOR) inhibition
Gnant M
Expert Rev of Anticancer Ther 2012; 12: 1579-89
305
2,652IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 35 -
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women withmetastatic breast cancer
Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F,Gnant M, Zielinski CC, Steger GG
Eur J Cancer 2012; 48: 1932-8
306
5,061IF:
The impact of menopause on bone and implications for breast cancer growth and metastasis
Hadji P, Coleman R, Gnant M, Green J
Ann Oncol 2012; 23: 2782-90
307
7,384IF:
Direct and indirect Anticancer Activity of Bisphosphonates: A review of published literature
Gnant M, Clezardin P
Cancer Treatm Rev 2012; 38: 407-15
308
6,054IF:
Axilladissektion bei positivem Sentinel-Lymphknoten - Ergebnisse Innsbrucker Konsuskonferenz
Hubalek M, Gnant M, Bartsch R, Kapp K, Lang A, Lax S, Lukas P, Neunteufel W, Reitsamer R, Sandbichler P, Schrenk P,Tamussino K, Pristauz G, Tschmelitsch J, Singer C, Zeimet A, Marth C
Geburtsh Frauenheilk 2012; 72:299–304
309
0,848IF:
8th European Breast Cancer Conference (EBCC-8)
Gnant M, Beermann B
Breast Care 2012; 7: 170-6
310
0,680IF:
Adjuvant bisphosphonates: a new standard of care?
Gnant M
Curr Opin Oncol 2012, 24:635-42
311
4,101IF:
Entwicklungen der forschenden Pharmaindustrie
Thomssen C, Gnant M, Harbeck N
Breast Care 2012; 7: 155-64
312
0,680IF:
Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer.
Arnold T, Micklmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R
Eur J Clin Invest 2013; 43:286-91
313
3,365IF:
The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of AdvancedBreast Cancer
Gnant M
Curr Oncol Rep 2013; 15: 14-23
314
2,545IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 36 -
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
Dubsky P, Filipits M, Jakesz R, Rudas M, Singer C, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D,Schmidt M, Gehrmann M, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M
Ann Oncol 2013; 24:640-7
315
7,384IF:
Health-related quality of life and disease symptoms in postmenopausal women with advanced breastcancer treated with everolimus plus exemestane versus exemestane monotherapy
Campone M, Lebrun F, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M,Hortobagyi GN, Nunzi M, Heng D, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J,Cahana A, Taran T, Sahmoud T, Burris HA
Curr Med Res Opinion 2013; 24: 2206-23
316
2,380IF:
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatmentwith anastrozole in postmenopausal patients with breast cancer - an analysis of the randomizedABCSG 6a trial
Gnant M, Pfeiler G, Stoeger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, StegerG, Samonigg H, Fesl C, Jakesz R, on behalf of the ABCSG
Brit J Cancer 2013; 109: 589-96
317
5,061IF:
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients
Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil T, Dietze O, Luisser I, Klug E, Sedivy R, Bachner R, Mayr D,Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M, on behalf of the ABCSG
Br J Cancer 2013; 109: 2959-64
318
5,082IF:
Microparticle-associated tissue factor activity in patients with pancreatic cancer: Correlation withclinicopathological features
Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A, Müllauer L, Gnant M, Scheithauer W, Pabinger I
Eur J Clin Invest 2013; 43: 277-85
319
3,365IF:
St. Gallen 2013: Brief preliminary summary of the Consensus discussion
Harbeck N, Thomssen C, Gnant M
Breast Care 2013; 8: 102-9
320
0,911IF:
Health-related Quality of Life of Advanced Breeast Cancer Patierns treated with Everolimus plusExemestane versus Placebo plus Exemestane in the Phase 3, randomized, controlled, BOLERO-2trial
Burris HA, Lebrun F, Hugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi G, Komorowski A,Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Rixxi JF, Bauly H, Taran T, Sahmoud T, Noguchi S
Cancer 2013; 119: 1908-15
321
3,662IF:
Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer - Summary andresults of an Austrian Expert Panel discussion
Gnant M, Greil R, Hubalek M, Steger G
Breast Care 2013; 8: 293-9
322
0,911IF:
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patientswith hormone-receptor positive breast cancer – an analysis of 1509 patients of the ABCSG-06 trial
Pfeiler G, Stoeger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U,Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, GreilR, Fesl C, Gnant M, on behalf of the ABCSG
Br J Cancer 2013; 108: 1408-14
323
5,082IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 37 -
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Study Group trial(ABCSG) 8
Goetz M, Suman V, Ames M, Gnant M, Filipits M, Hoskin T, Safgren S, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O,Lang A, Offner F, Reynolds C, Weinshilboum R, Ingle J
Clin Cancer Res 2013; 19: 500-7
324
7,837IF:
Effect of visceral metastases on the efficacy and safety of Everolimus in postmenopausal woem withadvanced breast cancer: subgroup analysis from the BOLERO-2 study
Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L,Burris HA, Hart LL, Melichar B, Hoartobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimi M, TaranT, Sahmoud T, Piccart M
Eur J Cancer 2013; 49: 2621-32
325
5,061IF:
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 finalprogression-free survival analysis.
Yardley DA, Noguchi S, Prichard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Capone M, Pistilli B, Piccart M,Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Fend W, Cahana A, Taran T, Sahmoud T, Lebwohl D, Rugo HS
Adv Ther 2013; 30:870-84
326
2,125IF:
Aromatase inhibitors with or without a gonadotropin-releasing hormone analogue in male breastcancer patients: a case series
Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnant M,Dimopoulos MA, Bartsch R
Br J Cancer 2013; 108: 2259-63
327
5,082IF:
Personalizing the treatment of women with early breast cancer: highlights of the St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, and Panel Members
Ann Oncol 2013; 24: 2206-23
328
7,384IF:
Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus
Hadji P, Coleman R, Gnant M
Crit Rev Oncol Hematol 2013; 101-11
329
5,270IF:
Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review andMeta-Analysis
Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, MauriD
Oncologist 2013; 18 (4): 353-61
330
4,095IF:
Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive MetastaticBreast Cancer
Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, Gnant M, Steger GG, Zielinski CC, BartschR
Breast J 2013; 19:149-55
331
1,831IF:
Guidelines: Usefulness and Limitations
Gnant M
Breast Care 2013; 8: 172-173
332
0,911IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 38 -
Everolimus reduced bone marker levels and progressive disease in bone in BOLERO-2
Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M,Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI
J Nat Cancer Inst 2013; 105: 654-63
333
14,336IF:
Safety and Efficacy of Everolimus With Exemestane Versus Exemestane Alone in Elderly PatientsWith HER2-Negative, Hormone-Receptor-Positive Breast Cancer in BOLERO-2
Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csőszi T, Baselga J, Puttawibul P, PiccartM, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T,Sahmoud T, Gnant M
Clin Breast Cancer 2013, 13: 421-32
334
2,422IF:
Impact of Body Mass Index (BMI) on estradiol depletion by aromatase inhibitors in postmenopausalwomen with early breast cancer
Pfeiler G, Königsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, Zellinger J, Exner R, Seifert M, Singer C, Gnant M,Dubsky P
Br J Cancer 2013; 109: 1522-7
335
5,082IF:
Follow-up after breast cancer diagnosis
Thomssen C, Diel I, Gnant M, Goldmann-Posch U, Göschke C, Haidinger R, Janni W, Lin NU
Breast Care 2013; 8: 457-60
336
0,911IF:
German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axillain breast cancer.
AGO; DGS; SGS; ÖGS; Panelists; Executive Board Members, Hoffmann J, Souchon R, Lebeau A, Öhlschlegel C, GruberG, Rageth C, Weber W, Harbeck N, Janni W, Kreipe H, Fitzal F, Resch A, Bago-Horvath Z, Peintinger F
Eur J Cancer 2013; 49: 2277-83
337
4,819IF:
Role of Bisphosphonates in postmenopausal women with breast cancer
Gnant M
Cancer Treatm Rev 2014; 40: 476-84
338
6,024IF:
Standardization of morbidity assessment in breast cancer surgery using the Clavien DindoClassification
Panhofer P, Ferenc V, Schütz M, Gleiss A, Dubsky P, Jakesz R, Gnant M, Fitzal F
Int J Surg 2014; 12: 334-9
339
1,436IF:
Predicting distant recurrence in receptor-positive breast cancer patients with limitedclinicopathological risk: using the PAM50 score in 1,478 postmenopausal patients of the ABCSG-08trial treated with adjuvant endocrine therapy alone
Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Singer C, Jakesz R, DubskyP, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens W, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T,on behalf of the ABCSG
Ann Oncol 2014; 25: 339-45
340
7,384IF:
Distal gastrectomy in pancreaticoduodenectomy is associated with accelerated gastric emptying,enhanced postprandial release of GLP-1, and improved insulin sensitivity
Harmuth S, Wewalka M, Holst JJ, Nemecek R, Thalhammer S, Schmid R, Sahora K, Gnant M, Miholic J
J Gastrointest Surg 2014; 18: 52-9
341
2,361IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 39 -
HER2-positive breast cancer: a new piece of the puzzle
Gnant M, Bartsch R, Steger GG
Lancet Oncol 2014; 15: 668-9
342
24,229IF:
Incidence and time course of everolimus-related adverse events in postmenopausal women withhormone-receptor-positive advanced breast cancer: insights from BOLERO-2
Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, ChouinardE, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hshimi M, Taran T, Sahmoud T, Burris HA
Ann Oncol 2014; 25: 808-15
343
7,384IF:
The impact of educational materials on compliance and persistence rates with adjuvant aromataseinhibitor treatment: first year results from the Compliance of ARomatase Inhibitors AssessmenT InDaily practice through Educational approach (CARIATIDE) Study
Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P,Barni S, Deschamp V
Breast 2014; 23: 393-9
344
3,929IF:
The PAM50 risk-of-recurrence (ROR) score predicts risk for late distant recurrence after endocrinetherapy in postmenopausal women with endocrine-responsive early breast cancer: A study on 1,246patients from the ABCSG-8 trial
Filipits M, Nielsen T, Rudas M, Greil, R, Stöger H. Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C,Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C,Ferree S, Liu S, Cowens JW, Gnant M
Clin Cancer Res 2014; 20: 1298-305
345
7,837IF:
Present and Future Breast Cancer Management - Bench to Bedside and Back: A Positioning Paperof Academia, Regulatory Authorities and Pharmaceutical Industry
Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR,Llombart A, Massacesi C, vonMinckwitz G, Penult-Llorca F, Scaltriti M, Wein W, Yarden Y, Zwierzina H, Zielinski CC, forthe Biotherapy Development Association (BDA)
Ann Oncol 2014; 25: 773-80
346
7,384IF:
Gemcitabine-based neoadjuvant chemotherapy for locally advanced pancreatic cancer does notaffect mortality and morbidity after pancreatic resection
Sahora K, Schindl M, Kuehrer I, Werba G, Fitzal F, Goetzinger P, Gnant M
European Surgery 2013; in press DOI 10.1007/s10353-013-0213-0
347
0,148IF:
Taxanes plus Trastuzumab compared to oral Vinorelbine plus Trastuzumab in HER2-overexpressingmetastatic breast cancer patients
Bartsch R, Berghoff AS, Rudas M, Dubsky P, DeVries C, Sattlberger C, Mader MR, Sparber C, Fitzal F, Gnant M,Rottenfusser A, Zielinski CC, Preusser M, Steger GG
Cancer Chemotherapy and Pharmacology 2014 [in press]
348
2,795IF:
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathologicalcomplete response to taxan-based neoadjuvant chemotherapy
Foedermayr M, Sebesta M, Rudas M, Berghoff A, Promberger R, Preusser M, Dubsky P, Fitzal F, Gnant M, Steger G,Welermann A, Zielinski C, Zach O, Bartsch R
Cancer Chemother Pharmacol 2014; 73: 771-8
349
2,571IF:
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breastcancer: final results of a randomized phase III study (ABCSG-24).
Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, StoegerH, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M; onbehalf of the Austrian Breast and Colorectal Study Group (ABCSG
Ann Oncol 2014; 25:366-71
350
7,384IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 40 -
Impact of the reconstruction method on delayed gastric emptying after pylorus-preservingpancreaticoduodenectomy: A prospective randomized study
Tamandl D, Sahora K, Prucker J, Schmid R, Holst JJ, Miholic J, Goetzinger P, Gnant M
World J Surg 2014; [published ahead of print Oct 12, 2013]
351
2,348IF:
The multigene signature MammaPrint® impacts on multidisciplinary team decisions in ER-positive,HER2-negative early breast cancer
Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retèl V, Fitzal F, Rudas M, Singer C, Pfeiler G, Gnant M, Jakesz R,Dubsky P
Brit J Cancer 2014; 111: 837-42
351
4,817IF:
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-yearbreast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomisedtrials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet 2014; 383: 2127-35
352
39,207IF:
Modern therapeutic concepts of early breast cancer
Gnant M
Breast Care (Basel) 2014; 92: 85-6
353
0,911IF:
Change of Body Mass Index (BMI) during adjuvant endocrine therapy and its impact on treatmentefficacy in premnopausal patients with breast cancer: an analysis of the ABCSG-12 trial
Pfeiler G, Königsberg R, Fesl C, Greil R, Stoeger H, Singer C, Knauer M, Steger G, Seifert M, Dubsky P, Fitzal F, Balic M,Bjelic-Radisic V, Mlineritsch B, Marth, C, Gnant M, on behalf of the ABCSG
Brit J Cancer 2014 [in press]
354
4,817IF:
Promoter methylation status of PCDH10, SPARC, and UCHL1 predict survival in stage II colorectalcancer patients treated with or without 5-fluorouracil-based chemotherapy
Heitzer E, Mach M, Filipits M, Resel M, Graf R, Weiszenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F,Boehm G, Hoefler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N
Modern Pathology 2014; 27: 906-15
356
7,837IF:
A phase II trial of two durations of bevacizumab added to neoadjuvant gemcitabine for borderline andlocally advanced pancreatic cancer
Sahora K, Schindl M, Kuehrer I, Eisenhut A, Werba G, Brostjan C, Teleky B, Ba'ssalamah A, Stift J, Schoppmann SF,Gnant M
Anticancer Res 2014; 34: 2377-84
357
1,872IF:
Preparing for prospective clinical trials - a national initiative of an excellence registry for consecutivepancreatic cancer resections
Gangl O, Sahora K, Kornprat P, Margreiter C, Primavesi F, Bareck E, Schindl M, Laengle F, Oefner D, Mischinger HJ,Pratschke J, Gnant M, Fuegger R
World J Surg 2014; 38: 456-62
358
3,373IF:
The genomic expression test Endopredict® is a prognostic tool for identifying risk of local recurrencein postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomizedwithin the prospective ABCSG 8 trial
Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R, Gnant M
Brit J Cancer 2015 [in press]
359
4,817IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 41 -
Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negativebreast cancer patients.
Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, Dubsky P, Gnant M, Steger GG,Weltermann A, Zielinski CC, Zach O, Bartsch R
J Hum Genetics 2015 [submitted]
360
IF:
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2.
Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd,Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J.
Ann Oncol. 2014; 25: 2357-62
361
IF:
Co-overexpression of HER2/HER3 is a predictor of imparied survival in breast cancer patients
Berghoff A, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, Rudas M, Streubel B, Dubsky P, Gnant M,Fitzal F, Zielinski CC, Birner P
Breast 2014; 23: 637-43
362
2,581IF:
Cost-Effectiveness of prognostic gene expression signature-based stratification of early breastcancer patients
Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD,Kronenwett R, Schwenkglenks M, Gnant M
Pharmacoeconomics 2015: 33: 179-90
363
IF:
The AURORA initiative for metastatic breast cancer.
Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C,Campbell P, Dinh P, von Minckwitz G, Gelber RD, Dowsett M, Di Leo A, Cameron D, Baselga J, Gnant M, Goldhirsch A,Norton L, Piccart M.
Br J Cancer. 2014; 111: 1881-7
364
IF:
Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis ofPatients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, TamoxifenAlone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M
J Clin Oncol 2014; Oct 20 online
365
18,370IF:
Patient-level meta-analysis of randomised trials of aromatase inhibitors versus tamoxifen in 31,920postmenopausal women with ER-positive early breast cancer
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)*
Lancet 2015 [submitted]
366
IF:
Taxanes plus Trastuzumab compared to oral Vinorelbine plus Trastuzumab ind HER2-overexpressingmetastatic breast cancer
Bergen E, .............. Gnant M,...., Bartsch R
Breast Care 2015; [in press]
367
0,911IF:
Effects of adjuvant bisphosphonate treatment on early breast cancer disease outcomes: A meta-analysis ofindividual patient data from randomised trials
Coleman R, Powles T, Gnant M, bnm
Lancet 2015 [accepted]
368
20,000IF:
2
Univ. Prof. Dr. Michael Gnant Originalarbeiten - 42 -
Ten-year analyses of the BIG 2-98 phase III trial with an exploratory analysis on the role of Ki67 inpredicting benefit of adjuvant docetaxel in patients with estrogen receptor positive breast cancer
Sonnenblick A, Azim HA Jr, de Azambuja E, Francis P, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, AmeyeL, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J
[submitted]
369
IF:
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plusovarian function suppression in premenopausal early breast cancer: of the Austrian Breast andColorectal Cancer Study Group Trial 12
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V,Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R, on behalf of the ABCSG
Ann Oncol 2015; 26; 313-20
370
6,578IF:
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positivehormone receptor positive early stage breast cancer treated with endocrine therapy: A combinedanalysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and Intrinsic Subtype
Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R,Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J
Ann Oncol 2015 [submitted]
371
6,578IF:
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advancedrectal cancer--a phase II clinical trial.
Eisterer W, De Vries A, Öfner D, Rabl H, Koplmüller R, Greil R, Tschmelitsch J, Schmid R, Kapp K, Lukas P, Sedlmayer F,Höfler G, Gnant M, Thaler J; ABCSG
Anticancer Res 2014; 34: 6767-73
372
1,872IF:
CDK4/6 inhibitors in luminal breast cancer
Gnant M, Steger GG, Bartsch R
Lancet Oncol 2015; 16: 2-3
373
24,725IF:
Activity of T-DM1 in HER2-positive breast cancer brain metastases
Bartsch R, Berghof AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, OehlerR, Zielinski CC, Gnant M, Steger GG, Preusser M
Neurooncology 2015 [submitted]
374
5,286IF:
Does patient education work in breast cancer? Final results from the global CARIATIDE study
Markopoulos C, Neven P, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P,Barni S, Deschamp V
Future Oncol. 2015; 11: 205-17
375
IF:
Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from aEuropean Panel.
Hadji P*, Coleman RE*, Wilson C, Powles T, Clezardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, DiLeo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thuerlimann B, Untch M, Cortes J, Martin M, AlbertUS, Conte PF, Ejlertsen B, Bergh J, M Kaufmann, I Holen.
Ann Oncol 2015 [submitted]
376
IF:
2